For elderly patients with advanced NSCLC who lack targeted driver gene mutations and exhibit low PD-L1 expression, platinum-containing doublet combination therapy is the recommended first-line treatment option for those who are suitable (76). Here, CD274 is linked to non-small cell lung carcinoma.